title: A MYCN-amplified cell line derived from a long-term event-free survivor among our sixteen established neuroblastoma cell lines.
abstract: Although more than 110 neuroblastoma (NB) cell lines have been established, there have been neither reports on the rate of success to establish NB cell lines, nor well-documented NB cell lines from long-term-survivors. We attempted to establish NB cell lines from 114 patients. Sixteen NB cell lines were established from 12 patients. The success rates to establish cell lines were 1.4% (1/70) from patients in early stages, 25.0% (11/44) from those in advanced stages, and 10.5% (12/114) from those in all stages respectively. Eleven of these 12 patients eventually died. The surviving patient, who was in stage 4 with MYCN-amplification, has been event-free for 19 years after completing therapy. The serum MYCN DNA level in patient TK was very high before therapy, decreased after chemotherapy, and has remained at the normal levels until now. The gene expression profiling of the primary tumor and the K-N-TK cell line was analyzed with an NB-specific cDNA microarray, and indicated that the probability of 5-year survival was extremely low. Microarray-based comparative genomic hybridization (CGH) analysis indicated that genomic aberration profiles of the cell line were uncommon, with MYCN amplification, 17q gain and 11q loss. A unique KP-N-TK cell line, established from an event-free survivor, will be a useful tool for investigating how a patient can survive a tumor with an extremely poor prognosis.
authors.affiliation: Saiseikai Shiga Hospital, Saiseikai Imperial Gift Foundation Inc., Ritto, Shiga, Japan. tosugimo@koto.kpu-m.ac.jp
authors.forename: Tohru
authors.initials: T
authors.lastname: Sugimoto
authors.forename: Takahiro
authors.initials: T
authors.lastname: Gotoh
authors.forename: Sigeki
authors.initials: S
authors.lastname: Yagyu
authors.forename: Hiroshi
authors.initials: H
authors.lastname: Kuroda
authors.forename: Tomoko
authors.initials: T
authors.lastname: Iehara
authors.forename: Hajime
authors.initials: H
authors.lastname: Hosoi
authors.forename: Sigeru
authors.initials: S
authors.lastname: Ohta
authors.forename: Miki
authors.initials: M
authors.lastname: Ohira
authors.forename: Akira
authors.initials: A
authors.lastname: Nakagawara
mesh_terms: D014408:Biomarkers, Tumor / Q000235:genetics* / Q000378:metabolism; D015153:Blotting, Western; D001859:Bone Neoplasms / Q000235:genetics* / Q000401:mortality / Q000556:secondary; D002675:Child, Preschool; D002869:Chromosome Aberrations; D055028:Comparative Genomic Hybridization; D005784:Gene Amplification; D020869:Gene Expression Profiling; D006801:Humans; D007223:Infant; D000071447:N-Myc Proto-Oncogene Protein; D009367:Neoplasm Staging; D009447:Neuroblastoma / Q000235:genetics* / Q000401:mortality / Q000473:pathology; D009687:Nuclear Proteins / Q000235:genetics*; D020411:Oligonucleotide Array Sequence Analysis; D015513:Oncogene Proteins / Q000235:genetics*; D011379:Prognosis; D012333:RNA, Messenger / Q000235:genetics; D060888:Real-Time Polymerase Chain Reaction; D020133:Reverse Transcriptase Polymerase Chain Reaction; D015996:Survival Rate; D017741:Survivors; D013997:Time Factors; D014407:Tumor Cells, Cultured
chemical_list: D014408:Biomarkers, Tumor; C459801:MYCN protein, human; D000071447:N-Myc Proto-Oncogene Protein; D009687:Nuclear Proteins; D015513:Oncogene Proteins; D012333:RNA, Messenger